Posttransplant outcomes
At the patient-level there were more 30-day mortalities (4.1%
non-induction vs 3.1% induction, p<0.001) and fewer patients
requiring dialysis after OHT (9.4% non-induction vs 11.6% induction,
p<0.001) in the non-induction therapy group. Nevertheless,
this difference was not sustained when we compared the center-level
outcomes among induction therapy utilization terciles (Figure 2).
Approximately 16.2% (n=2,845) of patients had an episode of rejection
requiring pharmacological intervention within the first year after OHT.
No differences were observed among the groups with 16.2% (n=955),
16.3% (n=951) and 16.1% (n=939) patients developing drug-treated
rejection within 1-year in the low, intermediate and high induction
terciles, respectively (p=0.47). Overall 25 centers had rates of
rejection above 20% and these were evenly distributed among the groups
(Figure 3). When patients were stratified by their pre-OHT rejection
risk score, no center-level correlation was observed between the
drug-treated rejection rate and induction therapy utilization (R=0.03
for low, R=0.03 for moderate and r=0.04 for high risk;
p<0.001) (Figure 4).